Literature DB >> 1717572

Recognition of the influenza hemagglutinin by class II MHC-restricted T lymphocytes and antibodies. I. Site definition and implications for antigen presentation and T lymphocyte recognition.

L R Brown1, N R Nygard, M B Graham, C Bono, V L Braciale, J Gorka, B D Schwartz, T J Braciale.   

Abstract

We have identified the site encompassing residues 126-145 on the A/Japan/57 influenza hemagglutinin molecule that is recognized in association with HLA-DRw11 by a clonal population of human, influenza specific, CD4+ cytolytic T lymphocytes. The critical core sequence of the T cell determinant spans hemagglutinin residues 129-140 and overlaps a putative antibody binding site. Hemagglutinins of influenza field strains that are not recognized by the T cell clones contain sequence alterations within the 129-140 target site of the CD4+ T cells. Functional analyses, with synthetic peptides, of the contribution of each of the residues within the sequence toward the capacity of the antigenic fragment to associate with both the restriction element and the TCR revealed a continuous linear array of residues necessary for MHC binding and/or Ag receptor engagement. At least one residue, the lysine at position 134, was shown to be critical for both DRw11 association and TCR recognition. The significance of these findings for recognition of glycoproteins by human CD4+ T cells is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717572

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  The effect of a single amino acid substitution within the V3 loop of HIV-1 gp120 on HLA-DR1-restricted CD4 T-cell recognition.

Authors:  M H Fernandez; A Faith; J A Higgins; J Weber; A D Rees
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

2.  A lung-specific neo-antigen elicits specific CD8+ T cell tolerance with preserved CD4+ T cell reactivity. Implications for immune-mediated lung disease.

Authors:  R I Enelow; M H Stoler; A Srikiatkhachorn; C Kerlakian; S Agersborg; J A Whitsett; T J Braciale
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

3.  Identification of T-cell epitopes on E2 protein of rubella virus, as recognized by human T-cell lines and clones.

Authors:  D Ou; P Chong; Y Choi; P McVeigh; W A Jefferies; G Koloitis; A J Tingle; S Gillam
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

4.  Antigenic sequences of poliovirus recognized by T cells: serotype-specific epitopes on VP1 and VP3 and cross-reactive epitopes on VP4 defined by using CD4+ T-cell clones.

Authors:  B P Mahon; K Katrak; K H Mills
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

5.  Human cytotoxic T-lymphocyte repertoire to influenza A viruses.

Authors:  J Jameson; J Cruz; F A Ennis
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

6.  Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLA-DR1-restricted CD4 T-cell response to influenza virus hemagglutinin.

Authors:  Katherine A Richards; Francisco A Chaves; Frederick R Krafcik; David J Topham; Christopher A Lazarski; Andrea J Sant
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

7.  Human CD4+ T-cell repertoire of responses to influenza A virus hemagglutinin after recent natural infection.

Authors:  C M Gelder; K I Welsh; A Faith; J R Lamb; B A Askonas
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

8.  Presentation of newly synthesized glycoproteins to CD4+ T lymphocytes. An analysis using influenza hemagglutinin transport mutants.

Authors:  D J Kittlesen; L R Brown; V L Braciale; J P Sambrook; M J Gething; T J Braciale
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

9.  Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein.

Authors:  K W Wucherpfennig; J L Strominger
Journal:  Cell       Date:  1995-03-10       Impact factor: 41.582

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.